In a mere nine months, Eli Lilly accomplished an unprecedented feat: The drug giant took a blood sample from one of the first U.S. patients to recover from Covid-19, identified an antibody that could fight the virus, and created a version of the antibody to treat people with the disease. Riley Griffin spoke to Lilly's CEO David Ricks about the challenges facing the company and its new treatment amid the worsening pandemic.

<p>In a mere nine months, Eli Lilly accomplished an unprecedented feat: The drug giant took a blood sample from one of the first U.S. patients to recover from Covid-19, identified an antibody that could fight the virus, and created a version of the antibody to treat people with the disease. Riley Griffin spoke to Lilly's CEO David Ricks about the challenges facing the company and its new treatment amid the worsening pandemic.</p>

For much of human history, we’ve turned to diets to lose weight and improve our health. But it’s mostly been in vain. No matter how much the number on the scale drops begins to go down, chances are that the weight will come back. That’s just what the science says. But when it comes to weight, the facts just don’t seem to matter. Losing It, a new series from Bloomberg’s Prognosis, looks at how we got weight loss so wrong — and whether there’s a better way forward.

<p>For much of human history, we’ve turned to diets to lose weight and improve our health. But it’s mostly been in vain. No matter how much the number on the scale drops begins to go down, chances are that the weight will come back. That’s just what the science says. But when it comes to weight, the facts just don’t seem to matter. Losing It, a new series from Bloomberg’s Prognosis, looks at how we got weight loss so wrong — and whether there’s a better way forward.</p>

Prognosis: Losing it

Prognosis: Losing It

Can We Make Enough Covid Drugs?

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/ddb94667-3504-4369-8b39-ae39008d3f65/transcript

Advertisement